Statera BioPharma (Statera BioPharma) Interest Expense : $-4.69 Mil (TTM As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Statera BioPharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Statera BioPharma's interest expense for the three months ended in Sep. 2022 was $ -1.81 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2022 was $-4.69 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Statera BioPharma's Operating Income for the three months ended in Sep. 2022 was $ -1.47 Mil. Statera BioPharma's Interest Expense for the three months ended in Sep. 2022 was $ -1.81 Mil. Statera BioPharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Statera BioPharma Interest Expense Historical Data

The historical data trend for Statera BioPharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Statera BioPharma Interest Expense Chart

Statera BioPharma Annual Data

Trend

Dec19

Dec20

Dec21

Interest Expense

-0.12

-1.13

-4.56

Statera BioPharma Quarterly Data
	Dec19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Interest Expense	Get a 7-Day Free Trial						-3.09	-1.10	-1.15	-0.64	-1.81

Statera BioPharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.69 Mil.

Statera BioPharma (OTCPK:STAB) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Statera BioPharma's Interest Expense for the three months ended in Sep. 2022 was $-1.81 Mil. Its Operating Income for the three months ended in Sep. 2022 was $-1.47 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2022 was $0.69 Mil.

Statera BioPharma's Interest Coverage for the quarter that ended in Sep. 2022 is calculated as

Statera BioPharma did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Statera BioPharma (Statera BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Statera BioPharma Inc (OTCPK:STAB) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

4333 Corbett Drive, Suite 1082, Fort Collins, CO, USA, 80525

Website

https://www.staterabiopharma.com

Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.

Executives

Satishchandran Chandrasekhar	director	167 CARMELA COURT, JUPITER FL 33478
Taunia Markvicka	director, officer: Chief Operating Officer	2537 RESEARCH BOULEVARD, SUITE 201, FORT COLLINS CO 80526
Robert Buckheit	officer: Chief Technology Officer	C/O CYTOCOM INC., 2537 RESEARCH BLVD, SUITE 201, FORT COLLINS CO 80526
Mcavoy Cozette M.	officer: Chief Legal Officer	2537 RESEARCH BOULEVARD, SUITE 201, FORT COLLINS CO 80526
Michael K Handley	director, officer: President and CEO	9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Clifford Selsky	officer: Chief Medical Officer	2537 RESEARCH BOULERVARD, SUITE 201, FORT COLLINS CO 80526
Peter Aronstam	officer: Chief Financial Officer	2537 RESEARCH BLVD, SUITE 201, FORT COLLINS CO 80526
Steve K Barbarick	director	TRACTOR SUPPLY COMPANY, 5401 VIRGINIA WAY, BRENTWOOD TN 37027
Christopher Zosh	officer: Vice President of Finance	C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET, BUFFALO NY 14203
Ivan Fedyunin	director	73 HIGH STREET, BUFFALO NY 14203
John Edward Szydlo	officer: Principal Financial Officer	73 HIGH STREET, BUFFALO NY 14203
Alexander Andryushechkin	director	73 HIGH STREET, BUFFALO NY 14203
Daniil Talyanskiy	director	73 HIGH STREET, BUFFALO NY 14203
Lea Verny	director	73 HIGH STREET, BUFFALO NY 14203
Alexey Nechaev	director	73 HIGH STREET, BUFFALO NY 14203